FDA Stalls on Accelerated Nod, Seeks More Data on Eteplirsen
Sarepta Therapeutics Inc. disclosed Monday afternoon following the market's close that the FDA has asked for additional information from its existing eteplirsen dataset before making a determination about a new drug application filing for the drug under Subpart H accelerated approval.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter